BMRA Key Statistics, Chart & Performance
The current stock price of BMRA is 2.58 USD. In the past month the price increased by 3.2%. In the past year, price increased by 2.77%.
BMRA Latest News, Press Relases and Analysis
BMRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.14 | 218.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.99 | 192.25B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.38 | 137.24B | ||
| SYK | STRYKER CORP | 26.89 | 135.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.93 | 57.34B | ||
| IDXX | IDEXX LABORATORIES INC | 55.84 | 56.23B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.33 | 48.21B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.29 | 38.25B | ||
| RMD | RESMED INC | 25.48 | 36.82B | ||
| DXCM | DEXCOM INC | 36 | 26.12B | ||
| PODD | INSULET CORP | 64.7 | 20.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.32 | 18.15B |
Related stock screener links
About BMRA
Company Profile
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. The company is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Company Info
BIOMERICA INC
17571 Von Karman Avenue
Irvine CALIFORNIA 92614 US
CEO: Zackary S. Irani
Employees: 64
Phone: 19493792875
BIOMERICA INC / BMRA FAQ
What does BMRA do?
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. The company is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
What is the stock price of BIOMERICA INC today?
The current stock price of BMRA is 2.58 USD.
What is the dividend status of BIOMERICA INC?
BMRA does not pay a dividend.
What is the ChartMill rating of BIOMERICA INC stock?
BMRA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is BIOMERICA INC worth?
BIOMERICA INC (BMRA) has a market capitalization of 7.61M USD. This makes BMRA a Nano Cap stock.
BMRA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BMRA. When comparing the yearly performance of all stocks, BMRA is a bad performer in the overall market: 70.93% of all stocks are doing better.
BMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BMRA. While BMRA seems to be doing ok healthwise, there are quite some concerns on its profitability.
BMRA Financial Highlights
Over the last trailing twelve months BMRA reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS increased by 44.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.33% | ||
| ROE | -70.9% | ||
| Debt/Equity | 0 |